Article
Evaluating discordant somatic calls across mutation discovery approaches to minimize false negative drug-resistant findings
2023-10-30
Abstract excerpt
Evaluating robustness of somatic mutation detections is essential when utilizing whole exome sequencing (WES) for treatment decision-making. A comprehensive evaluation was conducted using tumor WES from the FDA-led Sequencing Quality Control Phase 2 (SEQC2) project, in which multiple library kits sequenced identical DNA materials across three labs to benchmark analytical validity. These workflows included various...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 8048bd15-d6ff-5a42-b01c-3388b74dbdca
- DOI
- 10.1101/2023.10.26.562640
